We focus on development of novel and breakthrough therapies for unmet medical needs in any therapeutic area where a scientific, medical and business opportunity arises.
Areas of our interest are:
Currently we have under development a drug for a serious autoimmune condition:
AUR-1001 IS THE FIRST IN CLASS COMPOUND FOR THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME (HUGHES SYNDROME)